Suppr超能文献

中性粒细胞胞外诱捕网在肌层浸润性膀胱癌新辅助化疗中的预测价值

Predictive Value of Neutrophil Extracellular Traps in Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer.

作者信息

Shang Bingqing, Hu Zhilong, Xie Ruiyang, Wu Jie, Qu Wang, Zhang Wen, Zhou Aiping, Feng Lin, Bi Xingang, Shou Jianzhong

机构信息

Department of Urology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Department of Breast Medical Oncology, Zhejiang Cancer Hospital, Hangzhou, China.

出版信息

Mol Carcinog. 2025 Feb;64(2):305-316. doi: 10.1002/mc.23844. Epub 2024 Nov 14.

Abstract

Cisplatin-based chemotherapy is the recommended therapy for muscle-invasive bladder cancer (MIBC). However, the efficacy of MIBC for chemotherapy is only about 40%. Therefore, predictors of therapy response are urgently needed. Neutrophils form neutrophil extracellular traps (NETs), a network structure, and growing evidence indicated that it could be a prognostic and predictive marker in cancer. In MIBC, the predictive role of NETs in chemotherapy resistance is unclear. We used the Least Absolute Shrinkage and Selection Operator (LASSO) logistic regression analyses to develop a NETs-associated signature score (NETs-score) for therapeutic response prediction in the discovery cohort (GSE169455). Then the NETs score-based risk stratification was verified in two validation cohorts (Taber et al.'s cohort, our institutional cohort). In the training cohort, high NETs-score was associated with poor chemotherapy response (AUC = 0.781) and reduced recurrence-free survival (RFS) (hazard ratio [HR] = 2.07, 95% confidence interval [CI]: [1.26-3.40], p = 0.003) in MIBC patients. The NETs-score was also demonstrated to be a predictive factor for the efficacy of neoadjuvant chemotherapy in the validation cohort (AUC = 0.731). The accuracy of the NETs-score was superior to other chemotherapy response predictors such as Ba/Sq expression subtype (AUC = 0.711), BRCA2 mutation (AUC = 0.692) and ERCC2 mutation (AUC = 0.548). Furthermore, in our center cohort, the expression level of H3Cit showed a significant difference between the response and no-response group (p = 0.01). Through immunohistochemical validation, NETs was an independent predictor of MIBC neoadjuvant chemotherapy efficacy as determined by the multivariate logistic regression analysis (OR = 5.94, 95% CI: 1.20-45.50, p = 0.045). Patients with high levels of NETs predicted poor response to neoadjuvant chemotherapy. This study was the first to reveal the correlation between the level of NETs in MIBC and the efficacy of chemotherapy, which may provide a theoretical basis regarding NETs inhibitors.

摘要

基于顺铂的化疗是肌肉浸润性膀胱癌(MIBC)的推荐治疗方法。然而,MIBC化疗的疗效仅约为40%。因此,迫切需要治疗反应的预测指标。中性粒细胞形成中性粒细胞胞外陷阱(NETs),这是一种网络结构,越来越多的证据表明它可能是癌症的预后和预测标志物。在MIBC中,NETs在化疗耐药中的预测作用尚不清楚。我们使用最小绝对收缩和选择算子(LASSO)逻辑回归分析来开发一种与NETs相关的特征评分(NETs评分),用于在发现队列(GSE169455)中预测治疗反应。然后在两个验证队列(Taber等人的队列、我们机构的队列)中验证基于NETs评分的风险分层。在训练队列中,高NETs评分与MIBC患者化疗反应差(AUC = 0.781)和无复发生存期(RFS)降低(风险比[HR]=2.07,95%置信区间[CI]:[1.26 - 3.40],p = 0.003)相关。NETs评分在验证队列中也被证明是新辅助化疗疗效的预测因素(AUC = 0.731)。NETs评分的准确性优于其他化疗反应预测指标,如Ba/Sq表达亚型(AUC = 0.711)、BRCA2突变(AUC = 0.692)和ERCC2突变(AUC = 0.548)。此外,在我们的中心队列中,H3Cit的表达水平在反应组和无反应组之间存在显著差异(p = 0.01)。通过免疫组化验证,NETs是多变量逻辑回归分析确定的MIBC新辅助化疗疗效的独立预测因素(OR = 5.94,95% CI:1.20 - 45.50,p = 0.045)。NETs水平高的患者预测对新辅助化疗反应差。本研究首次揭示了MIBC中NETs水平与化疗疗效之间的相关性,这可能为NETs抑制剂提供理论依据。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验